Claims for Patent: 10,196,442

Summary for Patent: 10,196,442

Title:	Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49)
Abstract:	Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.
Inventor(s):	Reyes; Christopher L. (San Diego, CA), Chu; Peter (San Diego, CA), Tan; Xiangyang (Tewksbury, MA), Graff; Christilyn (Cambridge, MA), Yang; Weixing (Newton, MA)
Assignee:	Bionomics Inc. (San Diego, CA)
Application Number:	14/966,342
Patent Claims:	1. A method of inhibiting growth of a colon cancer tumor in a subject, comprising: administering an effective amount of a monoclonal antibody to a subject in need of treatment for colon cancer, wherein the monoclonal antibody binds to a G-Protein Coupled Receptor 49 (GPR49) polypeptide having the amino acid sequence of SEQ ID NO: 1, and wherein the administration of the monoclonal antibody inhibits growth of the colon cancer tumor in the subject by 65% or less over four weeks of treatment. 2. The method of claim 1, wherein the monoclonal antibody is administered in combination with an additional chemotherapeutic agent. 3. The method of claim 2, wherein the additional chemotherapeutic agent is irinotecan. 4. The method of claim 1, wherein the tumor is resistant to treatment with an agent selected from the group consisting of panitumumab and cetuximab. 5. The method of claim 1, wherein the tumor comprises a mutation in a human gene selected from the group consisting of K-Ras, PI3K, PTEN, p53, H-Ras, APC, TP53, FGFR2, VANGL2, STK11, JAK2, and RB1. 6. The method of claim 5, wherein the tumor comprises a mutation in a human K-Ras gene. 7. The method of claim 1, wherein the tumor comprises a solid tumor. 8. The method of claim 1, wherein the tumor comprises colon adenocarcinoma cells. 9. The method of claim 1, wherein the tumor comprises colon cancer stem cells. 10. The method of claim 2, wherein the effective amount of the monoclonal antibody is sufficient to reduce the rate of tumor growth in the subject. 11. The method of claim 1, wherein the effective amount of the monoclonal antibody is sufficient to increase survival of the subject compared to a subject having a tumor and not administered the monoclonal antibody. 12. The method of claim 1, wherein the monoclonal antibody is murine. 13. The method of claim 1, wherein the monoclonal antibody lacks specific binding to leucine-rich repeat containing G-protein-coupled receptor 4 (LGR4). 14. The method of claim 1, wherein the monoclonal antibody lacks specific binding to leucine-rich repeat containing G-protein-coupled receptor 6 (LGR6). 15. The method of claim 1, wherein the monoclonal antibody specifically binds to murine GPR49. 16. The method of claim 1, wherein the subject is mammalian. 17. The method of claim 1, wherein the subject is human. 18. A method of inhibiting growth of a colon cancer tumor in a subject, comprising: administering an effective amount of a monoclonal antibody to a subject in need of treatment for a colon cancer in combination with an additional chemotherapeutic agent comprising irinotecan, wherein the monoclonal antibody binds to a G-Protein Coupled Receptor 49 (GPR49) polypeptide having the amino acid sequence of SEQ ID NO: 1, and wherein the administration of the monoclonal antibody and additional chemotherapeutic agent inhibits growth of the colon cancer tumor in the subject by 65% or less over four weeks of treatment. 19. The method of claim 18, wherein the additional chemotherapeutic agent further comprises 5-fluorouracil (5-FU), or folinic acid (leucovorin).

Details for Patent 10,196,442

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-11-01
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2031-11-01
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2031-11-01